The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma

Blood

Volumn 94, Issue 1, 1999, Pages 233-243

  Illidge, Timothy M ^a   Cragg, Mark S ^a   McBride, Harry M ^a   French, Ruth R ^a   Glennie, Martin J ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD19; MONOCLONAL ANTIBODY CD22; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY; TARGET ORGAN;

EID: 0033168299     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.1.233.413a25_233_243     Document Type: Article

References (52)

1. Horning SJ: Treatment approaches to the low-grade lymphomas. Blood 83:881, 1994
2. 131 anti-B1 antibody for previously untreated follicular lymphoma (FL): Initial experience. J Clin Oncol 17:2a, 1998 (abstr)
3. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher DR, Porter B, Matthews DC, Fisher LD, Bernstein ID: Radiolabelled antibody therapy of B cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219, 1993
4. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, Bernstein ID: Phase-II trial of I-131 B1 (anti-CD20) antibody therapy with autologous stem-cell transplantation for relapsed B-cell lymphomas. Lancet 346: 336, 1995
5. Liu S, Eary JF, Martin P, Maloney DG, Appelbaum FR, Matthews DC, Bernstein ID, Press OW: Long-term follow-up of patients with relapsed B cell lymphomas treated with Iodine-131-labeled anti-CD20 (B1) antibody and autologous stem cell rescue. J Clin Oncol 16:13a, 1997 (abstr)
6. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL: Radioimmunotherapy of B-cell lymphoma with [I-131] anti-B1 (anti-CD20) antibody. N Eng J Med 329:459, 1993
7. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL: Iodine-131-Anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974, 1996
8. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillolopez A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R: Yttrium-90-labeled anti-CD20 monoclonal-antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457, 1996
9. Davis TA, Goris ML, Trisler KD, Negrin R, Liles TM, Fowler SF, Deb N, Becker M, Marquez CM, Ning S, Levy R, Knox S: (90)-yttrium labeled anti-CD20 therapy for recurrent B-cell lymphoma. Blood 86:1080, 1995
10. Grillolopez AJ, Chinn P, Morena R, Varns C, Parker E, Solinger AM: Phase-I study of IDEC-Y2B8 - 90-yttrium labeled anti-CD20 monoclonal-antibody therapy of relapsed non-Hodgkin's-lymphoma. Blood 86:207, 1995
11. Epstein AL, Marder RJ, Winter NJ, Stathopoulos E, Chen F, Parker JW, Taylor CR: Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47: 830, 1987
12. DeNardo SJ, DeNardo GI, Macey DJ, Mills SL, Ogrady LF, Mcgahan JP, Hu E, Epstein AL: Dose fractionated radioimmunotherapy of lymphoma with I-131 Lym-1. Br J Cancer 59:313, 1989
13. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16:3246, 1998
14. Parker BA, Vassos AB, Halpern SE, Miller RA, Hupt H, Amos DG, Simoni JL, Starr RJ, Green MR, Royston J: Radioimmunotherapy of B-cell lymphoma with 90-Y-conjugated anti-idiotype monoclonal antibody. Cancer Res 50:1022s, 1990 (suppl)
15. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R, Hansen HJ, Shevitz J, Leung O, Rubin AD, Herskovic T, Hanley D, Goldenberg DM: Treatment of non-Hodgkin's lymphoma with radiolabelled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 55:S5899, 1995
16. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murphy S, Goldenberg H, Lee RE, Stein R, Sigel JA, Izon DO, Burger K, Swayne LC, Belisle E, Hansen HJ, Pinsky CM: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labelled LL2 monoclonal antibody. J Clin Oncol 9:548, 1991
17. Czuczman MS, Sraus DJ, Divgi CR, Graham M, Garinchesa P, Finn R, Myers J, Old LJ, Lawson SM, Scheinberg DA: Phase I dose escalation of iodine 131-labelled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 11:2021, 1993
18. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Bernstein ID: Treatment of refractory non-Hodgkin's lymphoma with radiolabelled MB-1 (anti-CD37) antibody. J Clin Oncol 7:1027, 1989
19. Press OW, Appelbaum FR, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Thomas ED: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584, 1987
20. Press OW, Farr AG, Borroz KI: Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49:4906, 1989
21. Press OW, Howell-Clark J, Anderson S, Bernstein ID: Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83:1390, 1994
22. Vervoordeldonk SF, Merle PA, Van Leeuwen EF, Von dem Borne AEG: Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. Cancer 73:1006, 1994
23. Maloney DG, Grillolopez AJ, White C, Bodkin D, Schilder RJ, Neidhart J, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphomas. Blood 90:2188, 1997
24. Maloney DG, Grillolopez AJ, Bodkin D, White C, Liles TM, Royston I, Varns C, Rosenberg J, Levy R: IDEC-C2B8: Results of a Phase 1 multiple-dose trial in patients with relapsed non-Hodgkin's lymphomas. J Clin Oncol 15:3266, 1997
25. Shan D, Ledbetter JA, Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibody. Blood 91:1644, 1998
26. Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS: Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res 52:637, 1992
27. Badger CC, Krohn KK, Peterson AV, Shulman H, Bernstein ID: Experimental radioimmunotherapy of murine lymphoma with 131-labeled anti-Thy 1.1 monoclonal antibody. Cancer Res 45:1536, 1985
28. Badger CC, Bernstein ID: Monoclonal antibody therapy of murine leukemia. J Exp Med 157:828, 1983
29. Redwood WR, Tom TD, Strand M: Specificity, efficacy, and toxicity of radioimmunotherapy in erythroleukemic mice. Cancer Res 44:5681, 1984
30. Knox SJ, Levy R, Miller RA, Uhland W, Schiele J, Ruehl W, Finston R, Goris ML: Determinants of the antitumor effect of radiolabelled antibodies. Cancer Res 50:4935, 1990
31. Knox SJ, Sutherland W, Goris ML: Determinants of low dose rate effects associated with radioimmunotherapy. Antibody Immunoconj Radiopharm 6:197, 1993
32. Slavin S, Strober S: Spontaneous murine B-cell leukemia. Nature 272:624, 1978
33. 1): Organ distribution and kinetics of growth as determined by fluorescence analysis with an anti-idiotype antibody. J Immunol 123:1928, 1979
34. 1). I. Cell surface expression of IgM, IgD, Ia, and FcR. J Immunol 123:992, 1979
35. 1 can be activated by LPS to secrete IgM. J Immunol 125:976, 1980
36. Tutt AL, French RR, Illidge TM, Honeychurch J, McBride HM, Penfold CA, Fearon DT, Parkhouse ME, Klaus GGB, Glennie MJ: Monoclonal antibody therapy: Signaling activity on tumor cells appears more important than recruitment of effectors. J Immunol 161:3176, 1998
37. 1 act primarily with heavy chain determinants. Hybridoma 10:219, 1991
38. Krop I, de Fougeroules AR, Hardy RR, Allson M, Schlissel MS, Fearon DT: Self-renewal of B-1 lymphocytes is dependent on CD19. Eur J Immunol 26:238, 1996
39. Torres R, Law CL, Santosarguedo L, Kirkham PA, Grabstein K, Parkhouse ME, Clarke EA: Identification and characterization of the murine homologue CD22, a lymphocyte-B-restricted adhesion molecule. J Immunol 149:2641, 1992
40. Elliott TJ, Glennie MJ, McBride HM, Stevenson GT: Analysis of the interaction of antibodies with immunoglobulin idiotype on neoplastic cells. J Immunol 138:981, 1987
41. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 139:271, 1991
42. Cragg MC, Zhang L, French RR, Glennie MJ: Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B cells. Br J Cancer 79:850, 1999
43. Loevinger R, Berman M: A revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet No 1 New York, NY, Society of Nuclear Medicine, 1976
44. 1) occurs spontaneously in vitro and in vivo. Immunol 55:59, 1985
45. 131I. Cancer Res 51:5921, 1991
46. 1 lymphoma with bispecific antibodies and iodine-131-labeled bivalent haptens. J Nucl Med 37:505, 1996
47. Schmidberger H, Buschbaum DJ, Blazar BR, Everson P, Vallera DA: Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody therapy of the T cell lymphoma EL4. Cancer Res 51:1883, 1991
48. Racila E, Schuermann RH, Picker LJ, Yefenof E, Tucker T, Chang W, Marches R, Street NE, Vitetta ES, Uhr JW: Tumor dormancy and signalling, II Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med 181:1539, 1995
49. Harrington EA, Bennett MR, Fanidi A, Evan GI: c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13:3286, 1994
50. Fischer G, Kent SC, Josoph L, Green DR, Scott DW: Lymphoma models for B cell activation and tolerance X. Anti-μ-mediated growth arrest and apoptosis of murine B cell lymphomas is prevented by the stabilization of myc. J Exp Med 179:221, 1994
51. Santana P, Pena LA, HaimovitzFriedman A, Martin S, Green D, McLoughlin M, CordonCardo C, Schuchman EH, Fuks Z, Kolesnick R: Acid schingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86:189, 1996
52. Zhang L, French RR, Chan HTC, O'Keefe TL, Cragg MS, Power MJD, Glennie MJ: The development of anti-CD79 monoclonal antibodies for treatment of B-cell neoplastic disease. Ther Immunol 2:191, 1995